celecoxib has been researched along with Urinary Bladder Neoplasms in 28 studies
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib, a selective cyclooxygenase‑2 inhibitor, has chemo‑preventive activity against different cancer types, including bladder cancer (BC)." | 7.91 | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. ( Chen, L; Deng, W; Fu, B; Huang, M; Li, Y; Liu, X; Wang, G; Wang, Y; Wu, Y; Zeng, T; Zhou, X; Zhou, Z, 2019) |
| "To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine." | 7.80 | Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis. ( Cavalcanti, BC; Dornelas, CA; Furtado, FN; Jamacaru, FV; Juanes, Cde C; Magalhães, HI; Melo, Nde O; Moraes, MO, 2014) |
| "An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C (MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters." | 7.79 | The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. ( Ancona, P; Azzariti, A; Colabufo, NA; Contino, M; Cormio, L; Niso, M; Pagliarulo, A; Pagliarulo, V, 2013) |
| "Allyl isothiocyanate (AITC) occurs in cruciferous vegetables that are commonly consumed by humans and has been shown to inhibit urinary bladder cancer growth and progression in previous preclinical studies." | 7.79 | Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. ( Bhattacharya, A; Li, Y; Shi, Y; Zhang, Y, 2013) |
| "Low-grade RT-4 and high-grade UM-UC-3 bladder cancer cells were treated with 0-50 muM celecoxib." | 7.75 | Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer. ( Burmeister, CB; Gee, JR; Havighurst, TC; Kim, K, 2009) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 7.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms." | 6.76 | A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011) |
| "The prognosis of muscle-invasive bladder cancer with metastasis is poor." | 5.43 | A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. ( Aono, Y; Horinaka, M; Miki, T; Morioka, Y; Sakai, T; Takamura, T; Taniguchi, T; Toriyama, S; Ukimura, O; Yasuda, S, 2016) |
| "Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients." | 5.30 | BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( Andrews, S; Blazeby, J; Bogle, R; Brough, R; Burnett, S; Cresswell, J; Cruickshank, C; Hall, E; Huddart, R; Johnson, M; Kelly, JD; Madaan, S; Maynard, L; Mostafid, H; Palmer, A; Porta, N; Protheroe, A; Tan, WS, 2019) |
| "Celecoxib, a selective cyclooxygenase‑2 inhibitor, has chemo‑preventive activity against different cancer types, including bladder cancer (BC)." | 3.91 | Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. ( Chen, L; Deng, W; Fu, B; Huang, M; Li, Y; Liu, X; Wang, G; Wang, Y; Wu, Y; Zeng, T; Zhou, X; Zhou, Z, 2019) |
| "To evaluate the genotoxicity of propolis and L-lysine, as well as their effects on the possible cellular damage in erythroblasts (bone marrow) and leukocytes (peripheral blood) caused by the carcinogen BBN (n - butyl - n {4 - hydroxybutyl} nitrosamine) in rats subjected to bladder carcinogenesis and treated with green propolis and L-lysine." | 3.80 | Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis. ( Cavalcanti, BC; Dornelas, CA; Furtado, FN; Jamacaru, FV; Juanes, Cde C; Magalhães, HI; Melo, Nde O; Moraes, MO, 2014) |
| "An in vitro model was developed to understand if celecoxib could synergize with Mitomycin C (MMC), commonly used for the prevention of non-muscle invasive bladder cancer recurrence, and eventually elucidate if the mechanism of interaction involves multi drug resistance (MDR) transporters." | 3.79 | The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. ( Ancona, P; Azzariti, A; Colabufo, NA; Contino, M; Cormio, L; Niso, M; Pagliarulo, A; Pagliarulo, V, 2013) |
| "Allyl isothiocyanate (AITC) occurs in cruciferous vegetables that are commonly consumed by humans and has been shown to inhibit urinary bladder cancer growth and progression in previous preclinical studies." | 3.79 | Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination. ( Bhattacharya, A; Li, Y; Shi, Y; Zhang, Y, 2013) |
| "To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment." | 3.76 | Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. ( Cunha, FX; Figueiredo, A; Garrido, P; Mota, A; Neto, P; Nunes, S; Parada, B; Pinto, R; Reis, F; Rocha-Pereira, P; Rodrigues-Santos, P; Ruivo, J; Sereno, J; Teixeira, F; Teixeira-Lemos, E, 2010) |
| "Celecoxib has demonstrated an outstanding inhibitory effect on bladder cancer chemoprevention, which might be due to its expected anti-inflammatory actions, as well as by anti-proliferatory and antioxidant actions." | 3.75 | Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. ( Cunha, MF; Figueiredo, A; Garrido, P; Mota, A; Parada, B; Pinto, AF; Pinto, R; Reis, F; Sereno, J; Teixeira, F; Teixeira-Lemos, E, 2009) |
| "Low-grade RT-4 and high-grade UM-UC-3 bladder cancer cells were treated with 0-50 muM celecoxib." | 3.75 | Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer. ( Burmeister, CB; Gee, JR; Havighurst, TC; Kim, K, 2009) |
| " We hypothesised that a combination of the cyclooxygenase 2 (COX-2) selective inhibitor celecoxib and intravesical bacillus Calmette-Guérin (BCG), an effective tumour immunoprophylaxis and ablative therapy for non-muscle-invasive bladder cancer, would be more effective than BCG alone." | 3.74 | Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. ( Davies, BR; Dovedi, SJ; Kelly, JD; Kirby, JA; Leung, H, 2008) |
| " In these studies, we evaluated the COX-2 inhibitor celecoxib in two rodent models of urinary bladder cancer." | 3.70 | Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. ( Grubbs, CJ; Hill, DL; Kelloff, GJ; Koki, AT; Leahy, KM; Lubet, RA; Masferrer, JL; Seibert, K; Steele, VE, 2000) |
| "Celecoxib was well tolerated, with similar adverse events and quality-of-life in both arms." | 2.76 | A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. ( Czerniak, BA; De la Cerda, J; Eagle, C; Grossman, HB; Lee, JJ; Lerner, SP; Liu, S; Palmer, JL; Richmond, E; Sabichi, AL; Viner, JL, 2011) |
| "The prognosis of muscle-invasive bladder cancer with metastasis is poor." | 1.43 | A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells. ( Aono, Y; Horinaka, M; Miki, T; Morioka, Y; Sakai, T; Takamura, T; Taniguchi, T; Toriyama, S; Ukimura, O; Yasuda, S, 2016) |
| "Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that has been reported to elicit anti-proliferative response in various tumors." | 1.38 | Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. ( Chen, SC; Chiang, CK; Chuang, YT; Huang, KH; Kuo, KL; Liu, SH; Pu, YS; Tsai, YC; Weng, TI, 2012) |
| "The human bladder cancer cell lines UM-UC-1, -3, and -6 were assayed for COX-2 expression by Western analysis using a monoclonal antibody to COX-2." | 1.33 | Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. ( Fischer, SM; Gee, J; Grossman, HB; Jendiroba, D; Lee, IL; Sabichi, AL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kamali, K | 1 |
| Nikbakht, J | 1 |
| Ayubi, E | 1 |
| Nabizadeh, M | 1 |
| Sarhadi, S | 1 |
| Kelly, JD | 4 |
| Tan, WS | 1 |
| Porta, N | 1 |
| Mostafid, H | 1 |
| Huddart, R | 1 |
| Protheroe, A | 1 |
| Bogle, R | 1 |
| Blazeby, J | 1 |
| Palmer, A | 1 |
| Cresswell, J | 1 |
| Johnson, M | 1 |
| Brough, R | 1 |
| Madaan, S | 1 |
| Andrews, S | 1 |
| Cruickshank, C | 1 |
| Burnett, S | 1 |
| Maynard, L | 1 |
| Hall, E | 3 |
| Gore, JL | 1 |
| Wright, JL | 1 |
| Goldstein, MR | 1 |
| Mascitelli, L | 1 |
| Liu, X | 1 |
| Wu, Y | 1 |
| Zhou, Z | 1 |
| Huang, M | 1 |
| Deng, W | 1 |
| Wang, Y | 1 |
| Zhou, X | 1 |
| Chen, L | 1 |
| Li, Y | 2 |
| Zeng, T | 1 |
| Wang, G | 1 |
| Fu, B | 1 |
| Pagliarulo, V | 1 |
| Ancona, P | 1 |
| Niso, M | 1 |
| Colabufo, NA | 1 |
| Contino, M | 1 |
| Cormio, L | 1 |
| Azzariti, A | 1 |
| Pagliarulo, A | 1 |
| Bhattacharya, A | 1 |
| Shi, Y | 1 |
| Zhang, Y | 1 |
| Huang, KH | 2 |
| Kuo, KL | 2 |
| Ho, IL | 1 |
| Chang, HC | 1 |
| Chuang, YT | 2 |
| Lin, WC | 1 |
| Lee, PY | 1 |
| Chang, SC | 1 |
| Chiang, CK | 2 |
| Pu, YS | 2 |
| Chou, CT | 1 |
| Hsu, CH | 1 |
| Liu, SH | 2 |
| Blazeby, JM | 1 |
| Aaronson, NK | 1 |
| Lloyd, L | 1 |
| Waters, R | 1 |
| Fayers, P | 1 |
| Dornelas, CA | 1 |
| Cavalcanti, BC | 1 |
| Magalhães, HI | 1 |
| Jamacaru, FV | 1 |
| Furtado, FN | 1 |
| Juanes, Cde C | 1 |
| Melo, Nde O | 1 |
| Moraes, MO | 1 |
| Kurtova, AV | 1 |
| Xiao, J | 1 |
| Mo, Q | 1 |
| Pazhanisamy, S | 1 |
| Krasnow, R | 1 |
| Lerner, SP | 2 |
| Chen, F | 1 |
| Roh, TT | 1 |
| Lay, E | 1 |
| Ho, PL | 1 |
| Chan, KS | 1 |
| Toriyama, S | 1 |
| Horinaka, M | 1 |
| Yasuda, S | 1 |
| Taniguchi, T | 1 |
| Aono, Y | 1 |
| Takamura, T | 1 |
| Morioka, Y | 1 |
| Miki, T | 1 |
| Ukimura, O | 1 |
| Sakai, T | 1 |
| Qin, J | 1 |
| Yuan, J | 1 |
| Li, L | 1 |
| Liu, H | 1 |
| Qin, R | 1 |
| Qin, W | 1 |
| Chen, B | 1 |
| Wang, H | 1 |
| Wu, K | 1 |
| Parada, B | 2 |
| Sereno, J | 2 |
| Reis, F | 2 |
| Teixeira-Lemos, E | 2 |
| Garrido, P | 2 |
| Pinto, AF | 1 |
| Cunha, MF | 1 |
| Pinto, R | 2 |
| Mota, A | 2 |
| Figueiredo, A | 2 |
| Teixeira, F | 2 |
| Gee, JR | 1 |
| Burmeister, CB | 1 |
| Havighurst, TC | 1 |
| Kim, K | 1 |
| Dhawan, D | 2 |
| Craig, BA | 1 |
| Cheng, L | 1 |
| Snyder, PW | 1 |
| Mohammed, SI | 1 |
| Stewart, JC | 2 |
| Zheng, R | 2 |
| Loman, RA | 1 |
| Foster, RS | 1 |
| Knapp, DW | 2 |
| Cunha, FX | 1 |
| Rocha-Pereira, P | 1 |
| Neto, P | 1 |
| Ruivo, J | 1 |
| Rodrigues-Santos, P | 1 |
| Nunes, S | 1 |
| Sabichi, AL | 2 |
| Lee, JJ | 1 |
| Grossman, HB | 2 |
| Liu, S | 1 |
| Richmond, E | 1 |
| Czerniak, BA | 1 |
| De la Cerda, J | 1 |
| Eagle, C | 1 |
| Viner, JL | 1 |
| Palmer, JL | 1 |
| Lubet, RA | 2 |
| Clapper, ML | 1 |
| McCormick, DL | 1 |
| Pereira, MA | 1 |
| Chang, WC | 1 |
| Steele, VE | 2 |
| Fischer, SM | 2 |
| Juliana, MM | 1 |
| Grubbs, CJ | 2 |
| Chen, SC | 1 |
| Weng, TI | 1 |
| Tsai, YC | 1 |
| Gee, J | 1 |
| Lee, IL | 1 |
| Jendiroba, D | 1 |
| Zhang, J | 1 |
| Xu, ZQ | 1 |
| Hu, Q | 1 |
| Qiu, XW | 1 |
| Wang, ZR | 1 |
| Dovedi, SJ | 1 |
| Kirby, JA | 1 |
| Davies, BR | 1 |
| Leung, H | 1 |
| Brandau, S | 1 |
| Jeffreys, AB | 1 |
| Ziegler, J | 1 |
| Koki, AT | 1 |
| Leahy, KM | 1 |
| Masferrer, JL | 1 |
| Kelloff, GJ | 1 |
| Hill, DL | 1 |
| Seibert, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for celecoxib and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Comparison of the Efficacy of Oxybutynin, Phenazopyridine, Celecoxib, and Placebo in the Treatment of Urinary Tract Symptoms after BCG Therapy in Patients with Bladder Tumors.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Celecoxib; Female; Humans; | 2020 |
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 2019 |
Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhi | 2014 |
Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio | 2010 |
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Male | 2011 |
23 other studies available for celecoxib and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Can We Prevent Bladder Cancer Recurrences?
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Re: John L. Gore, Jonathan L. Wright. Can We Prevent Bladder Cancer Recurrences? Eur Urol 2019;75:602-3.
Topics: Carcinoma, Transitional Cell; Celecoxib; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplas | 2019 |
Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis.
Topics: Antineoplastic Agents; Celecoxib; Cell Line; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Epitheli | 2019 |
The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP B | 2013 |
Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caspases; Celecoxib; Cel | 2013 |
Celecoxib-induced cytotoxic effect is potentiated by inhibition of autophagy in human urothelial carcinoma cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Transitional Cell | 2013 |
Potential chemoprotective effects of green propolis, L-lysine and celecoxib on bone marrow cells and peripheral blood lymphocytes of Wistar rats subjected to bladder chemical carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Bone Marrow Cells; Carcinogenesis; Carcinogenicity Tests; Celecoxi | 2014 |
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.
Topics: Animals; Antibodies, Neutralizing; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclo | 2015 |
A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Caspases; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell P | 2016 |
In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Line, Tumor; Cel | 2009 |
Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cell Growth Processes; Cyclooxygenase 2 Inhibitors; Inf | 2009 |
Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Cycle; Ce | 2009 |
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Celecoxib; Cyclooxygenase 2 Inhibito | 2010 |
Boxing bladder cancer with COX-2-specific inhibition.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Male; Neoplasm Recurrence, Local; Pyrazoles; | 2011 |
Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Bexarotene; Celecoxib; Co | 2012 |
Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells.
Topics: Apoptosis; Catechin; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2 Inhibitors; Down-R | 2012 |
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cell Prolif | 2006 |
[Effects of selective cyclooxygenase-2 inhibitor on proliferation and apoptosis of human bladder cancer cell line T24].
Topics: Apoptosis; bcl-2-Associated X Protein; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygena | 2007 |
Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Analysis of Variance; Animals; BCG Vaccine; Blotting, Western; Carcinoma, Transitional Cell; Celecox | 2008 |
Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Topics: Animals; BCG Vaccine; Carcinoma, Transitional Cell; Celecoxib; Cyclooxygenase Inhibitors; Dinoprosto | 2008 |
Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Celecoxib; Cell Line, Tumor; Cell Prolif | 2008 |
Early trials probe COX-2 inhibitors' cancer-fighting potential.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1999 |
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Squamous Cel | 2000 |